↓ Skip to main content

Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100

Overview of attention for article published in Frontiers in immunology, January 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
4 X users
patent
1 patent
facebook
3 Facebook pages

Readers on

mendeley
83 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
Published in
Frontiers in immunology, January 2013
DOI 10.3389/fimmu.2013.00493
Pubmed ID
Authors

Kevin Tse, Ayelet Gonen, John Sidney, Hui Ouyang, Joseph L. Witztum, Alessandro Sette, Harley Tse, Klaus Ley

Abstract

Background: Subsets of CD4(+) T-cells have been proposed to serve differential roles in the development of atherosclerosis. Some T-cell types are atherogenic (T-helper type 1), while others are thought to be protective (regulatory T-cells). Lineage commitment toward one type of helper T-cell versus another is strongly influenced by the inflammatory context in which antigens are recognized. Immunization of atherosclerosis-prone mice with low-density lipoprotein (LDL) or its oxidized derivative (ox-LDL) is known to be atheroprotective. However, the antigen specificity of the T-cells induced by vaccination and the mechanism of protection are not known. Methods: Identification of two peptide fragments (ApoB3501-3516 and ApoB978-993) from murine ApoB-100 was facilitated using I-Ab prediction models, and their binding to I-Ab determined. Utilizing a vaccination scheme based on complete and incomplete Freund's adjuvant (CFA and IFA) [1 × CFA + 4 × IFA], we immunized Apoe(-/-)mice with ApoB3501-3516 or ApoB978-993 emulsified in CFA once and subsequently boosted in IFA four times over 15 weeks. Spleens, lymph nodes, and aortas were harvested and evaluated by flow cytometry and real time RT-PCR. Total atherosclerotic plaque burden was determined by aortic pinning and by aortic root histology. Results: Mice immunized with ApoB3501-3516 or ApoB978-993 demonstrated 40% reduction in overall plaque burden when compared to adjuvant-only control mice. Aortic root frozen sections from ApoB3501-3516 immunized mice showed a >60% reduction in aortic sinus plaque development. Aortas from both ApoB3501-3516 and ApoB978-993 immunized mice contained significantly more mRNA for IL-10. Both antigen-specific IgG1 and IgG2c titers were elevated in ApoB3501-3516 or ApoB978-993 immunized mice, suggesting helper T-cell immune activity after immunization. Conclusion: Our data show that MHC Class II restricted ApoB-100 peptides can be atheroprotective, potentially through a mechanism involving elevated IL-10.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Singapore 1 1%
Unknown 81 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 20%
Researcher 15 18%
Student > Bachelor 10 12%
Other 8 10%
Student > Master 6 7%
Other 12 14%
Unknown 15 18%
Readers by discipline Count As %
Agricultural and Biological Sciences 21 25%
Medicine and Dentistry 15 18%
Immunology and Microbiology 12 14%
Biochemistry, Genetics and Molecular Biology 7 8%
Pharmacology, Toxicology and Pharmaceutical Science 7 8%
Other 5 6%
Unknown 16 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 June 2019.
All research outputs
#6,373,631
of 25,374,647 outputs
Outputs from Frontiers in immunology
#6,616
of 31,516 outputs
Outputs of similar age
#61,957
of 288,991 outputs
Outputs of similar age from Frontiers in immunology
#74
of 503 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 31,516 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,991 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 503 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.